Alejandro
Martín García Sancho
Profesor Asociado CC. Salud
Hospital Vall d'Hebron
Barcelona, EspañaHospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (11)
2023
-
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study
British Journal of Haematology, Vol. 203, Núm. 2, pp. 182-193
2022
-
BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival
Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 101-108
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205
-
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
Blood Advances
2020
-
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Blood, Vol. 135, Núm. 13, pp. 996-1007
-
Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study
Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554
-
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era
European Journal of Haematology, Vol. 104, Núm. 5, pp. 400-408
-
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)
British Journal of Haematology, Vol. 188, Núm. 6, pp. 888-897
2019
-
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807
-
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966
2017
-
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI
British Journal of Haematology, Vol. 176, Núm. 6, pp. 918-928